Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)

H. H. Yoon; J. C. Bendell; F. S. Braiteh; I. Firdaus; P. A. Philip; A. L. Cohn; N. Lewis; D. M. Anderson; E. Arrowsmith; J. D. Schwartz; L. Gao; Y. Hsu; Y. Xu; D. Ferry; S. R. Alberts; Z. A. Wainberg

doi:10.1093/annonc/mdz454

Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)

H. H. Yoon
, J. C. Bendell
, F. S. Braiteh
, I. Firdaus
, P. A. Philip
, A. L. Cohn
, N. Lewis
, D. M. Anderson
, E. Arrowsmith
, J. D. Schwartz
, L. Gao
, Y. Hsu
, Y. Xu
, D. Ferry
, S. R. Alberts
, Z. A. Wainberg

Research output: Contribution to journal › Comment/debate

3 Scopus citations

Abstract

A sentence was omitted from the funding statement in the original article: 'Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA022453.' This has now been added to the online version of the article.

Original language	English
Pages (from-to)	2016
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	12
DOIs	https://doi.org/10.1093/annonc/mdz454
State	Published - 1 Dec 2019

Access to Document

10.1093/annonc/mdz454

Fingerprint

Dive into the research topics of 'Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)'. Together they form a unique fingerprint.

Cite this

Yoon, H. H., Bendell, J. C., Braiteh, F. S., Firdaus, I., Philip, P. A., Cohn, A. L., Lewis, N., Anderson, D. M., Arrowsmith, E., Schwartz, J. D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S. R., & Wainberg, Z. A. (2019). Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423). Annals of Oncology, 30(12), 2016. https://doi.org/10.1093/annonc/mdz454

Yoon, H. H. ; Bendell, J. C. ; Braiteh, F. S. et al. / Corrigendum : Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423). In: Annals of Oncology. 2019 ; Vol. 30, No. 12. pp. 2016.

@article{a213a5045c5347f282db10755db19f89,

title = "Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)",

abstract = "A sentence was omitted from the funding statement in the original article: 'Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA022453.' This has now been added to the online version of the article.",

author = "Yoon, \{H. H.\} and Bendell, \{J. C.\} and Braiteh, \{F. S.\} and I. Firdaus and Philip, \{P. A.\} and Cohn, \{A. L.\} and N. Lewis and Anderson, \{D. M.\} and E. Arrowsmith and Schwartz, \{J. D.\} and L. Gao and Y. Hsu and Y. Xu and D. Ferry and Alberts, \{S. R.\} and Wainberg, \{Z. A.\}",

year = "2019",

month = dec,

day = "1",

doi = "10.1093/annonc/mdz454",

language = "English",

volume = "30",

pages = "2016",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "12",

}

Yoon, HH, Bendell, JC, Braiteh, FS, Firdaus, I, Philip, PA, Cohn, AL, Lewis, N, Anderson, DM, Arrowsmith, E, Schwartz, JD, Gao, L, Hsu, Y, Xu, Y, Ferry, D, Alberts, SR & Wainberg, ZA 2019, 'Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)', Annals of Oncology, vol. 30, no. 12, pp. 2016. https://doi.org/10.1093/annonc/mdz454

Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423). / Yoon, H. H.; Bendell, J. C.; Braiteh, F. S. et al.
In: Annals of Oncology, Vol. 30, No. 12, 01.12.2019, p. 2016.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)

AU - Yoon, H. H.

AU - Bendell, J. C.

AU - Braiteh, F. S.

AU - Firdaus, I.

AU - Philip, P. A.

AU - Cohn, A. L.

AU - Lewis, N.

AU - Anderson, D. M.

AU - Arrowsmith, E.

AU - Schwartz, J. D.

AU - Gao, L.

AU - Hsu, Y.

AU - Xu, Y.

AU - Ferry, D.

AU - Alberts, S. R.

AU - Wainberg, Z. A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - A sentence was omitted from the funding statement in the original article: 'Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA022453.' This has now been added to the online version of the article.

AB - A sentence was omitted from the funding statement in the original article: 'Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA022453.' This has now been added to the online version of the article.

UR - https://www.scopus.com/pages/publications/85077462806

U2 - 10.1093/annonc/mdz454

DO - 10.1093/annonc/mdz454

M3 - Comment/debate

C2 - 31893488

AN - SCOPUS:85077462806

SN - 0923-7534

VL - 30

SP - 2016

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -

Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL et al. Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423). Annals of Oncology. 2019 Dec 1;30(12):2016. doi: 10.1093/annonc/mdz454